医学
瞬态弹性成像
内科学
血脂异常
脂肪肝
脂肪变性
糖尿病
胃肠病学
共感染
代谢综合征
超重
肝病
病毒性肝炎
丙型肝炎
乙型肝炎
肥胖
纤维化
肝纤维化
疾病
免疫学
人类免疫缺陷病毒(HIV)
内分泌学
作者
Juliana Fittipaldi,Sandra Wagner Cardoso,Estêvão Portela Nunes,Cristiane Fonseca de Almeida,Patrícia Dias de Brito,Valdilea Gonçalves Veloso,Beatriz Gilda Jegerhorn Grinsztejn,Hugo Perazzo
出处
期刊:AIDS
[Lippincott Williams & Wilkins]
日期:2025-06-04
卷期号:39 (12): 1721-1730
被引量:5
标识
DOI:10.1097/qad.0000000000004250
摘要
OBJECTIVE: To describe the association of metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant liver fibrosis (CSLF) in people with HIV from Rio de Janeiro (Brazil). DESIGN: Cross-sectional study. METHODS: We analyzed data from the baseline visit of the PROSPEC-HIV-study (NCT02542020). People with HIV aged ≥18 years were submitted to clinical evaluation, questionnaires, blood sample and transient elastography (TE) at INI/FIOCRUZ from June/2015 to March/2019. Exclusion criteria were unreliable TE or missing data. Steatosis and liver fibrosis were assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) from TE, respectively. MASLD was determined by presence of steatosis (TE-CAP ≥ 263 dB/m) with at least one cardiometabolic-risk-factor (overweight/obesity, diabetes, hypertension or dyslipidemia) without hazard alcohol intake. CSLF was defined by TE-LSM ≥8.0 kPa. Multivariate logistic regression models were performed. RESULTS: 684 participants [47.8% male, median age= 45 [interquartile range (IQR), 36-53] years, 12% with diabetes and 13% with viral hepatitis coinfection] were included. The prevalence [95% confidence interval (CI)] of MASLD and CSLF were 19.3% [16.5-22.4] and 14.2% [11.8-17.0], respectively. In the multivariate analysis [odds ratio (OR) (95% CI)], older age [1.52 (1.75-1.96)], MASLD [2.20 (1.25-3.87)], viral hepatitis [4.93 (2.72-8.94)], higher ALT levels [1.11 (1.04-1.18)] and CD4 + cell count <350 cells/mm 3 [1.95 (1.07-3.53)] were significantly associated with presence of CSLF. MASLD remained independently associated with CSLF in people with HIV mono-infection ( n = 595) [OR = 2.18 (95% CI, 1.19-3.98)]. CONCLUSION: MASLD increased the odds of CSLF in people with HIV independently of viral hepatitis. Strategies to screen MASLD in are of paramount importance to reduce the burden of liver disease in people with HIV.
科研通智能强力驱动
Strongly Powered by AbleSci AI